A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses. Each participant can receive up to 3 doses, with a minimum 7 day washout between dosing periods. Side effects will be documented. This study is approximately 9 weeks long, not including screening. Screening is required within 6 weeks prior to the start of the study.
Epistemonikos ID: cc8b32d1db6d205afe8433ad5b5e1d3905d87ce5
First added on: May 11, 2024